PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer
Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.
Study Summaries
KEYNOTE-B21: Pembrolizumab Plus Adjuvant Chemotherapy in High-Risk Endometrial Cancer
Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population
Korean HIPEC trial - IDS patients only 2023
HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.
Korean HIPEC Trial: HIPEC After Primary or Interval Cytoreductive Surgery in Ovarian Cancer
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Interlace Trial
Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.
COMPASSION-16: Cadonilimab for Persistent, Recurrent, or Metastatic Cervical Cancer
Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer
mEOC/GOG-0241: Oxaliplatin-Capecitabine vs. Carboplatin-Paclitaxel in Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.
GOG 205: Chemoradiation for Locally Advanced Vulvar Cancer
The combination of radiation therapy with weekly cisplatin chemotherapy is effective in achieving high complete clinical and pathological response rates with manageable toxicity for the treatment of locally-advanced vulvar carcinoma.